{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T14:15:28Z","timestamp":1795011328352,"version":"4.9.1"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2023,5,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Dry eye disease (DED) is a common public health problem with significant impact on vision-related quality of life and well-being of patients. Medications with rapid onset of action and a good tolerability profile remain an unmet need.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess efficacy, safety, and tolerability of a water-free cyclosporine ophthalmic solution, 0.1% (CyclASol [Novaliq GmbH]), applied twice daily in DED compared with vehicle.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (ESSENCE-2) was a phase 3, multicenter, randomized, double-masked, vehicle-controlled clinical study conducted from December 5, 2020, to October 8, 2021. Following a 14-day run-in period with an artificial tear administered 2 times per day, eligible participants were randomly assigned 1:1 to the treatment groups. Patients with moderate to severe DED were included in the study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Cyclosporine solution vs vehicle administered 2 times per day for 29 days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary end points were changes from baseline in total corneal fluorescein staining (tCFS; 0-15 National Eye Institute scale) and in dryness score (0-100 visual analog scale) at day 29. Conjunctival staining, central corneal fluorescein staining, and tCFS responders were also assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 834 study participants were randomly assigned to cyclosporine (423 [50.7%]) or vehicle (411 [49.3%]) groups at 27 sites. Participants had a mean (SD) age of 57.1\u2009(15.8) years, and 609 (73.0%) were female individuals. The majority of participants self-identified in the following race categories: 79 Asian (9.5 %), 108 Black (12.9%), and 635 White (76.1%). Participants treated with cyclosporine solution had greater improvement in tCFS (\u22124.0 grades) than the vehicle group (\u22123.6 grades) at day 29 (change [\u2206] = \u22120.4; 95% CI, \u22120.8 to 0; <jats:italic>P<\/jats:italic>\u2009=\u2009.03). The dryness score showed treatment benefits from baseline in both groups: \u221212.2 points for cyclosporine and \u221213.6 points for vehicle (\u2206 = 1.4; 95% CI, \u22121.8 to 4.6; <jats:italic>P<\/jats:italic>\u2009=\u2009.38). In the cyclosporine group, 293 participants (71.6%) achieved clinically meaningful reductions of 3 grades or higher in tCFS vs 236 (59.7%) in the vehicle group (\u2206 = 12.6%; 95% CI, 6.0%-19.3%; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001). These responders showed greater improvement in symptoms at day 29 including dryness (\u2206 = \u22124.6; 95% CI, \u22128.0 to \u22121.2; <jats:italic>P<\/jats:italic>\u2009=\u2009.007) and blurred vision (\u0394 = \u22123.5; 95% CI, \u22126.6 to \u22124.0; <jats:italic>P<\/jats:italic>\u2009=\u2009.03) compared with nonresponders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>The ESSENCE-2 trial confirmed that treatment with a water-free cyclosporine solution, 0.1%, results in early therapeutic effects on the ocular surface compared with vehicle. The responder analyses suggest that the effect is clinically meaningful in 71.6% of participants in the cyclosporine group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04523129\">NCT04523129<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2023.0709","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T15:03:09Z","timestamp":1680793389000},"page":"459","source":"Crossref","is-referenced-by-count":79,"title":["Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease"],"prefix":"10.1001","volume":"141","author":[{"given":"Esen K.","family":"Akpek","sequence":"first","affiliation":[{"name":"The Wilmer Eye Institute, The Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Wirta","sequence":"additional","affiliation":[{"name":"Eye Research Foundation, Newport Beach, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnathon E.","family":"Downing","sequence":"additional","affiliation":[{"name":"Premier Practice Management, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Tauber","sequence":"additional","affiliation":[{"name":"Tauber Eye Center, Kansas City, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Sheppard","sequence":"additional","affiliation":[{"name":"Virginia Eye Consultants, Norfolk"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph B.","family":"Ciolino","sequence":"additional","affiliation":[{"name":"Massachusetts Eye and Ear Infirmary\/Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice S.","family":"Meides","sequence":"additional","affiliation":[{"name":"Novaliq GmbH, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Kr\u00f6sser","sequence":"additional","affiliation":[{"name":"Novaliq GmbH, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"eoi230011r1","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1080\/09273948.2020.1841804","article-title":"Allergy and dry eye disease.","volume":"29","author":"Leonardi","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"eoi230011r2","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ajo.2017.06.033","article-title":"Prevalence of diagnosed dry eye disease in the US among adults aged 18 years and older.","volume":"182","author":"Farrand","year":"2017","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"eoi230011r3","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","article-title":"TFOS DEWS II pathophysiology report.","volume":"15","author":"Bron","year":"2017","journal-title":"Ocul Surf"},{"issue":"2","key":"eoi230011r4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/NHH.0000000000000652","article-title":"Dry eye disease: prevalence, assessment, and management.","volume":"36","author":"Rouen","year":"2018","journal-title":"Home Healthc Now"},{"issue":"5","key":"eoi230011r5","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jcrs.2019.03.023","article-title":"An algorithm for the preoperative diagnosis and treatment of ocular surface disorders.","volume":"45","author":"Starr","year":"2019","journal-title":"J Cataract Refract Surg"},{"issue":"2","key":"eoi230011r6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0002-9394(01)01365-4","article-title":"Impaired functional visual acuity of dry eye patients.","volume":"133","author":"Goto","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"eoi230011r7","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1097\/ICO.0000000000000998","article-title":"Mechanisms of visual disturbance in dry eye.","volume":"35","author":"Koh","year":"2016","journal-title":"Cornea"},{"issue":"3","key":"eoi230011r8","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II epidemiology report.","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul Surf"},{"issue":"5","key":"eoi230011r9","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/j.jcrs.0000000000000844","article-title":"Call to action: treating dry eye disease and setting the foundation for successful surgery.","volume":"48","author":"Donaldson","year":"2022","journal-title":"J Cataract Refract Surg"},{"issue":"3","key":"eoi230011r10","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II management and therapy report.","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul Surf"},{"issue":"1","key":"eoi230011r11","doi-asserted-by":"publisher","first-page":"P286","DOI":"10.1016\/j.ophtha.2018.10.023","article-title":"Dry Eye Syndrome Preferred Practice Pattern\u00ae.","volume":"126","author":"Akpek","year":"2019"},{"issue":"1","key":"eoi230011r12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejpb.2014.05.009","article-title":"Semifluorinated alkanes as a liquid drug carrier system for topical ocular drug delivery.","volume":"88","author":"Dutescu","year":"2014","journal-title":"Eur J Pharm Biopharm"},{"issue":"1-2","key":"eoi230011r13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ijpharm.2018.01.019","article-title":"Semifluorinated alkane-based systems for enhanced corneal penetration of poorly soluble drugs.","volume":"538","author":"Agarwal","year":"2018","journal-title":"Int J Pharm"},{"issue":"4","key":"eoi230011r14","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00417-016-3572-y","article-title":"A semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic option for topical treatment of dry eye.","volume":"255","author":"Gehlsen","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"eoi230011r15","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.ophtha.2019.01.024","article-title":"A clinical phase 2 study to assess efficacy, safety, and tolerability of water-free cyclosporine formulation for treatment of dry eye disease.","volume":"126","author":"Wirta","year":"2019","journal-title":"Ophthalmology"},{"issue":"10","key":"eoi230011r16","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1097\/ICO.0000000000002633","article-title":"A water-free 0.1% cyclosporine A solution for treatment of dry eye disease: results of the randomized phase 2B\/3 ESSENCE Study.","volume":"40","author":"Sheppard","year":"2021","journal-title":"Cornea"},{"issue":"4","key":"eoi230011r17","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease\u2014CsA Phase 3 study group.","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi230011r19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.5301\/ejo.5000779","article-title":"Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial.","volume":"26","author":"Leonardi","year":"2016","journal-title":"Eur J Ophthalmol"},{"issue":"9","key":"eoi230011r20","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.ophtha.2019.03.050","article-title":"A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease.","volume":"126","author":"Goldberg","year":"2019","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi230011r21","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s40123-022-00516-9","article-title":"Selective pharmacologic therapies for dry eye disease treatment: efficacy, tolerability, and safety data review from preclinical studies and pivotal trials.","volume":"11","author":"Shen Lee","year":"2022","journal-title":"Ophthalmol Ther"},{"issue":"11","key":"eoi230011r22","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1001\/jamaophthalmol.2021.3943","article-title":"Efficacy of lifitegrast ophthalmic solution, 5.0%, in patients with moderate to severe dry eye disease: a post hoc analysis of 2 randomized clinical trials.","volume":"139","author":"Holland","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"eoi230011r23","article-title":"NOV03 for dry eye disease associated with meibomian gland dysfunction: results of the randomized phase 3 GOBI study.","author":"Tauber","year":"2022","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi230011r24","doi-asserted-by":"publisher","first-page":"BIO168","DOI":"10.1167\/iovs.17-21831","article-title":"Evaluating corneal fluorescein staining using a novel automated method.","volume":"58","author":"Amparo","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"eoi230011r25","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1080\/09273948.2022.2027461","article-title":"Outcome measures to assess dry eye severity: a review.","volume":"30","author":"Hirabayashi","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"eoi230011r26","doi-asserted-by":"publisher","DOI":"10.1177\/25158414211012797","article-title":"The role of KPI-121 0.25% in the treatment of dry eye disease: penetrating the mucus barrier to treat periodic flares.","volume":"13","author":"Gupta","year":"2021","journal-title":"Ther Adv Ophthalmol"},{"issue":"3","key":"eoi230011r27","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ajo.2004.04.052","article-title":"A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance.","volume":"138","author":"Pflugfelder","year":"2004","journal-title":"Am J Ophthalmol"},{"issue":"13","key":"eoi230011r28","doi-asserted-by":"publisher","first-page":"9516","DOI":"10.1167\/iovs.11-8412","article-title":"Corneal fluorescein staining correlates with visual function in dry eye patients.","volume":"52","author":"Kaido","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"eoi230011r29","doi-asserted-by":"publisher","first-page":"6601","DOI":"10.1167\/iovs.14-15125","article-title":"Ocular forward light scattering and corneal backward light scattering in patients with dry eye.","volume":"55","author":"Koh","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"eoi230011r30","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1136\/bjophthalmol-2018-312333","article-title":"Effects of tear film dynamics on quality of vision.","volume":"102","author":"Koh","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"eoi230011r31","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.2147\/OPTH","article-title":"Real-world treatment patterns of cyclosporine ophthalmic emulsion and lifitegrast ophthalmic solution among patients with dry eye.","volume":"13","author":"White","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"eoi230011r18","unstructured":"Xiidra. Xiidra home page. Accessed November 2, 2022. https:\/\/www.xiidra.com"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2803655\/jamaophthalmology_akpek_2023_oi_230011_1684089004.22429.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T15:05:00Z","timestamp":1684422300000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2803655"}},"subtitle":["The ESSENCE-2 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.0709","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,1]]}}}